Drug Profile
PolyPEPI 1018
Alternative Names: PolyPEPI™ 1018; PolyPEPI™ 1018 CRC VaccineLatest Information Update: 08 Dec 2023
Price :
$50
*
At a glance
- Originator Treos Bio
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 20 Oct 2023 Efficacy and adverse events data from a phase II trial in Colorectal cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 11 Jun 2023 Mayo Clinic completes a phase I OBERTO-201 trial in Colorectal cancer (Adjunctive treatment, In adults, In the elderly, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (SC) (NCT05130060)
- 05 Jun 2023 Efficacy and immunogenicity data from a phase Ib OBERTO-201 trial in Colorectal cancer released by Treos Bio